肥胖症与GLP-1药物：一项基于理赔数据的分析（英）

Obesity andGLP-1 DrugsA Claims-Based AnalysisWHITE PAPERA FAIR Health White Paper, May 27, 2025Copyright 2025, FAIR Health, Inc. All rights reserved.aprilphoto Ⓒ 123RF.com 2 Obesity and GLP-1 Drugs Summary Obesity is a common and serious disease. In recent years, a new class of medications for obesity has become available: glucagon-like peptide-1 (GLP-1) receptor agonists. In this report, FAIR Health delves into its repository of over 51 billion commercial healthcare claim records, the nation’s largest such database, to examine trends in obesity and GLP-1 drug prescriptions among adult patients during the period 2019-2024. This study focuses on trends in diagnosis of overweight, obesity and type 2 diabetes, as well as GLP-1 drugs and other obesity treatment options (including bariatric surgery and behavioral health services). The key findings include the following: • From 2019 to 2024, the percentage of adult patients with a diagnosis of overweight or obesity increased from 10.4 percent in 2019 to 15.7 percent in 2024, a relative increase of 50.7 percent. As discussed below in the Results section, many adult patients who are overweight or obese may not receive a medical diagnosis of overweight or obesity.1 • The percentage of adult patients prescribed any type of GLP-1 drug increased from 0.9 percent of patients in 2019 to 4.0 percent of patients in 2024, a relative increase of 363.7 percent. • Among all adult patients prescribed a GLP-1 drug, the percentage who had an overweight or obesity diagnosis and no type 2 diabetes diagnosis increased from 3.7 percent in 2019 to 16.5 percent in 2024, a relative increase of 344.4 percent. • Over two percent of adult patients now take a GLP-1 drug to treat overweight or obesity. Among all adult patients, the percentage who had an overweight or obesity diagnosis and were prescribed a GLP-1 drug increased from 0.30 percent in 2019 to 2.05 percent in 2024, a relative increase of 586.7 percent. The percentage who received an overweight or obesity diagnosis but no type 2 diabetes diagnosis increased 1,960.9 percent, from 0.03 percent to 0.67 percent. • The percentage of younger adults (aged 18-39) prescribed a GLP-1 drug increased from 0.19 percent in 2019 to 1.33 percent in 2024, a relative increase of 587.8 percent. • Diagnoses of pancreatitis increased from 0.17 percent in the year before the first GLP-1 drug prescription to 0.31 percent in the year after for patients who did not have a type 2 diabetes diagnosis. This was an increase of over 80 percent, the largest percent increase among the co-occurring diagnoses examined. • From 2019 to 2024, the percentage of adult patients who had bariatric surgery decreased from 0.12 percent in 2019 to 0.07 percent in 2024, a relative decrease of 41.8 percent. • From 2019 to 2024, among all adult patients with an overweight or obesity diagnosis, the percentage who were prescribed a GLP-1 drug but did not have bariatric surgery increased from 2.5 percent in 2019 to 11.2